Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis

Author(s):

V. G. Hall, C. Lim, N. R. Saunders, E. Klimevski, T. H.O. Nguyen, L. Kedzierski, J. F. Seymour, V. Wadhwa, K. A. Thursky, M. K. Yong, K. Kedzierska, M. A. Slavin, B. W. Teh

Details:

Leukemia and Lymphoma, Volume 64, Issue 9, 2023-01-01

Article Link: Click here

Affiliations:

• Peter Maccallum Cancer Centre
• The Peter Doherty Institute for Infection and Immunity
• University of Melbourne